Select a Region North America

Assess Commercial Readiness in Europe

Unlock Opportunities in Europe With EVERSANA

Going Global to Deliver Value

The UK, EU4 and emerging markets across eastern Europe present a major opportunity for U.S. biotechnology companies. However, many such companies decide to license their products to partner companies, assuming that launching in Europe is complex. The result: Often, the product fails to achieve its full value. To be globally competitive, EVERSANA can work with you to assess and adapt your development and commercialization strategies to retain the value of your product.

Europe is Complex, but Not Complicated

Europe is a highly diverse market that provides significant opportunity for any company seeking to globalize its products. With a greater understanding of the region and the individual countries’ nuances, companies can make more informed choices, secure better deal terms with partners and explore their commercialization options. Unlike other markets, regulatory approval, price, reimbursement and access are all intimately linked in Europe. Most countries will not enter reimbursement, access or pricing discussions if a company has not begun the application process for marketing authorization or has one already.

European Commercial Readiness Assessment

Powered by our proprietary, best-in-class price and access platform NAVLIN Price & Access Data, the European Commercial Readiness Assessment helps companies assess their opportunity in Europe. Our team of experts will partner with you to ensure that you have the information you need to maximize your revenue potential.

Is this the right strategy for my product?

Schedule a complimentary 30-minute session to learn more.

Explore Our Services


    Built for the pharmaceutical and biotechnology industries, our global experts help industry executives address their most pressing business challenges.

    Learn More
  • Market Access & Reimbursement

    A partner you can trust to navigate today’s complex landscape

    Learn More

Related Articles

WEBINAR: Yes EU can! How novel treatments can avoid complexity and commercialize with impact across the European continent

Europe has a population of more than 450 million people, yet most manufacturers consider the U.S. the primary market for launch. In this webinar, EVERSANA’s Mike Ryan, Executive Vice President, Europe, discusses with other industry leaders how the EU’s landscape is changing in order for European states to increasingly become a priority market for commercialization. This […]

Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers

COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma with recent changes, including the Pharmaceutical Strategy for Europe. But one element of the European pharma industry that remains […]